You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH):收到 KYS202004A 注射液臨牀試驗批准通知書
格隆匯 09-05 17:32

格隆匯9月5日丨康緣藥業(600557.SH)公佈,公司近日收到國家藥品監督管理局簽發的KYS202004A注射液《藥物臨牀試驗批准通知書》。KYS202004A注射液是公司自主研發的一種雙靶點Fc融合蛋白,其擬用適應症為銀屑病(一種遺傳與環境共同作用誘發的免疫介導的慢性、複發性、炎症性、系統性疾病。臨牀表現為鱗屑性紅斑或斑塊,侷限或廣泛分佈)[1]。KYS202004A可以通過同時阻斷TNF-α與IL-17A的信號通路,抑制TNF-α與IL-17A介導的下游細胞因子、趨化因子的產生,從而有效控制炎症反應,減輕皮膚病變,緩解銀屑病臨牀症狀。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account